NCT02287961

Brief Summary

Multicentric epidemiological non-comparative study in France characterising evolution of anal Human papillomavirus (HPV) infection and related lesions and evaluating markers associated with the observed evolution. Estimated enrolment: 500 Principal Outcomes

  • Detection of high-grade cytological and histological anal lesions by high resolution anoscopy
  • Spontaneous regression of high-grade anal lesions
  • Detection of anal HPV infection Intervention (procedure):
  • Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
  • Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)
  • High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits) Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA): \- anal biopsy(ies) during HRA Only if high-grade lesion: \- HRA biannually

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
516

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 15, 2014

Completed
27 days until next milestone

First Posted

Study publicly available on registry

November 11, 2014

Completed
21 days until next milestone

Study Start

First participant enrolled

December 2, 2014

Completed
7.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

April 23, 2026

Status Verified

April 1, 2026

Enrollment Period

7.6 years

First QC Date

October 15, 2014

Last Update Submit

April 21, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Evaluation of high-grade anal lesions by high resolution anoscopy

    Initial inclusion visit

  • Evaluation of anal HPV infection by DNA, RNA and protein detection

    Initial inclusion visit

  • Quantification of spontaneous regression of high-grade anal lesions

    Month 24

Secondary Outcomes (4)

  • Evaluation of anal HPV infection by DNA, RNA and protein detection

    Month 6

  • Evaluation of anal HPV infection by DNA, RNA and protein detection

    Month 12

  • Evaluation of anal HPV infection by DNA, RNA and protein detection

    Month 18

  • Evaluation of anal HPV infection by DNA, RNA and protein detection

    Month 24

Study Arms (1)

Subjects

OTHER

* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)

Procedure: Standard proctologic examinationProcedure: High resolution anoscopyProcedure: Biopsy(ies) during High Resolution AnoscopyProcedure: High Resolution Anoscopy biannually

Interventions

(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits

Subjects

at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits

Subjects

only if lesion suggestive of AIN detected during High Resolution Anoscopy

Subjects

Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)

Subjects

Eligibility Criteria

Age35 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men who have sex with men
  • At least 35 years old
  • HIV-positive (documented search of HIV infection, with HIV status determined according to HAS algorithm)
  • Signed informed consent
  • Affiliated to or beneficiary of French social security
  • All severity criteria and evolution of HIV disease are accepted (including AIDS stage and co-infections)

You may not qualify if:

  • Contraindication to biopsy
  • History of anal cancer or pelvic radiotherapy
  • AIN2/3 treated during previous year
  • Difficulty in evaluation (anus reshaped and/or scarred)
  • Individual placed under judicial protection
  • Foreseen absence which may hamper participation; insufficient motivation; associated pathology with priority for care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diaconesses

Paris, France

Location

Related Publications (4)

  • Combes JD, Didelot JM, Radenne S, Zaegel-Faucher O, Lesage AC, Siproudhis L, Piroth L, Marchand L, Heard I, Hoyeau N, Henno S, Darragh TM, Alberts CJ, Clifford GM, Etienney I; ANRS-EP57-APACHES Study group. Cumulative Detection of Anal High-Grade Squamous Intraepithelial Lesions Over 2-Year Follow-up in Men Who Have Sex With Men Living With Human Immunodeficiency Virus in France. J Infect Dis. 2024 Jul 25;230(1):55-60. doi: 10.1093/infdis/jiad506.

    PMID: 39052708BACKGROUND
  • Alberts CJ, Heard I, Canestri A, Marchand L, Flejou JF, Piroth L, Ferry T, Didelot JM, Siproudhis L, Henno S, Poizot-Martin I, Darragh TM, Clifford GM, Combes JD, Etienney I; ANRS EP57 APACHES Study group. Incidence and Clearance of Anal Human Papillomavirus (HPV)-16 and HPV-18 Infection, and Their Determinants, Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in France. J Infect Dis. 2020 Apr 7;221(9):1488-1493. doi: 10.1093/infdis/jiz623.

  • Clifford GM, Siproudhis L, Piroth L, Poizot-Martin I, Radenne S, Reynes J, Lesage A, Heard I, Henno S, Flejou JF, Marchand L, Combes JD, Etienney I; ANRS EP57 APACHES Study group. Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM. AIDS. 2018 Oct 23;32(16):2363-2371. doi: 10.1097/QAD.0000000000001947.

  • Combes JD, Heard I, Poizot-Martin I, Canestri A, Lion A, Piroth L, Didelot JM, Ferry T, Patey O, Marchand L, Flejou JF, Clifford GM, Etienney I; ANRS EP57 APACHES Study group. Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men. J Infect Dis. 2018 Apr 23;217(10):1535-1543. doi: 10.1093/infdis/jiy059.

Related Links

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Isabelle Etienney

    Hôpital Diaconesses Paris

    PRINCIPAL INVESTIGATOR
  • Gary Clifford

    International Agency for Research on Cancer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2014

First Posted

November 11, 2014

Study Start

December 2, 2014

Primary Completion

June 30, 2022

Study Completion

June 30, 2022

Last Updated

April 23, 2026

Record last verified: 2026-04

Locations